- ROUNDTABLE: Pharmacy’s future in sync with technology
- FDA advisory panel to consider OTC status of NSAIDs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Senate passes Drug Quality and Security Act
ROSEMONT, Pa. — The Food and Drug Administration has approved a drug for treating nausea and vomiting during pregnancy.
Drug maker Duchesnay USA said the FDA approved Diclegis (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets in the 10 mg/10 mg strength for NVP, more commonly known as morning sickness, in women who don't respond to conservative treatment. NVP is estimated to affect 70-85% of pregnant women, and symptoms range from nausea to severe vomiting and retching that can last throughout the day.
The company said Diclegis was the first FDA-approved treatment for morning sickness in more than 30 years.
"The FDA approval of Diclegis provides an important new treatment to the millions of women suffering from nausea and vomiting of pregnancy and fills a 30-year void in the treatment of NVP," Duchesnay CEO Gilbert Godin said. "Duchesnay USA is honored to bring the only FDA-approved treatment to help control symptoms of morning sickness to market."
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.